First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer have?

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer has 2,585 citations in the OpenAlex counts ScholarIQ stores.

When was First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer published?

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer has 2017 year in the ScholarIQ index.

What is the open-access status of First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer?

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer has bronze oa status in the ScholarIQ index.

What is the DOI of First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer?

The DOI for First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer is on the source record.

What is the PMID of First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer?

The PMID for First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer is on the source record.

What is the OpenAlex record for First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer?

The OpenAlex for First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer is on the source record.